MedTrace Logo

Hemodynamic Effects of Spironolactone in Patients With Heart Failure

NCT00860340 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2014-12-10

No results posted yet for this study

Summary

To determine if the beneficial effect of spironolactone in patients with congestive heart failure is in part due to its intrinsic inotropic action.

Randomized, two group placebo controlled, single blind study.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

Spironolactone

100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.

Sponsors & Collaborators

  • University of Toledo Health Science Campus

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860340 on ClinicalTrials.gov